11/4/2013 9:54:47 AM
SCHAUMBURG, Ill., Nov. 4, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Carboplatin Injection, an antineoplastic agent, in four preservative-free vial presentations. According to IMS, for the 12 months ending September 2013, the US market for Carboplatin Injection approximated $30 million. As with all products in Sagent's portfolio, Carboplatin features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by